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Abstract
Background: Progranulin gene (GRN) mutations are major causes of frontotemporal lobar degeneration. To date,
68 pathogenic GRN mutations have been identified. However, very few of these mutations have been reported in
Asians. Moreover, some GRN mutations manifest with familial phenotypic heterogeneity. Here, we present a novel
GRN mutation resulting in frontotemporal lobar degeneration with a distinct clinical phenotype, and we review
reports of GRN mutations associated with familial phenotypic heterogeneity.
Case presentation: We describe the case of a 74-year-old woman with left frontotemporal lobe atrophy who
presented with progressive anarthria and non-fluent aphasia. Her brother had been diagnosed with corticobasal syndrome
(CBS) with right-hand limb-kinetic apraxia, aphasia, and a similar pattern of brain atrophy. Laboratory blood examinations
did not reveal abnormalities that could have caused cognitive dysfunction. In the cerebrospinal fluid, cell counts and
protein concentrations were within normal ranges, and concentrations of tau protein and phosphorylated tau protein were
also normal. Since similar familial cases due to mutation of GRN and microtubule-associated protein tau gene (MAPT) were
reported, we performed genetic analysis. No pathological mutations of MAPT were identified, but we identified a novel
GRN frameshift mutation (c.1118_1119delCCinsG: p.Pro373ArgX37) that resulted in progranulin haploinsufficiency.
Conclusion: This is the first report of a GRN mutation associated with familial phenotypic heterogeneity in Japan. Literature
review of GRN mutations associated with familial phenotypic heterogeneity revealed no tendency of mutation sites. The
role of progranulin has been reported in this and other neurodegenerative diseases, and the analysis of GRNmutations
may lead to the discovery of a new therapeutic target.
Keywords: Progranulin, Primary progressive aphasia, Corticobasal syndrome, Frontotemporal lobar degeneration,
Phenotypic heterogeneity, Case report
Background
Frontotemporal lobar degeneration (FTLD) is character-
ized by degeneration of the frontal and temporal lobes,
and presents as a clinically heterogeneous disease. The
pathological classification of FTLD is based on the
molecular features of the disease-associated inclusion-
forming proteins: FTLD-tau, FTLD-TDP, FTLD-FUS, and
FTLD-UPS. Clinically, FTLD is classified into two subsets:
behavioral variant FTLD (bvFTLD) and primary progres-
sive aphasia (PPA), the latter of which includes semantic
dementia and progressive non-fluent aphasia. In addition,
FTLD can be concomitant with corticobasal degeneration
(CBD), progressive supranuclear palsy (PSP), and motor
neuron disease (MND) [1].
Progranulin is widely expressed in the central nervous
system and is involved in immunomodulation as well as cell
growth and proliferation. Since the first demonstration of
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FTLD-associated progranulin gene (GRN) mutation in
2006 [2, 3], more than 150 GRN mutations have been iden-
tified, including 68 pathogenic mutations. FTLD due to a
GRN mutation is histopathologically characterized by
ubiquitin-positive and TDP-43-positive inclusion bodies.
While the most frequent clinical phenotype is bvFTLD,
PPA and corticobasal syndrome (CBS) have also been
reported [4–6]. There are also reports of clinical het-
erogeneity within a family [7, 8]. In addition, FTLD due
to a GRN mutation is rare in Asian individuals, with an
incidence of < 1% in Asians compared to an incidence
of 5–10% in Europeans [9, 10].
In this report, we present the case of a 74-year-old
Japanese woman with left-side atrophy in the frontal and
temporal lobes and symptoms of progressive anarthria
and non-fluent aphasia. We identified the cause to be a
novel frameshift mutation in GRN that caused progranu-
lin haploinsufficiency.
Case presentation
A 74-year-old woman was referred to our hospital and
admitted for progressive speech and language difficulties.
The patient was unable to recall the names of things or
persons and was unable to communicate with others for
about 1 year prior to admission, though she was able to
shop and do housework without difficulty. She had no
significant medical history; however, regarding her family
history, her elder brother had developed word-finding
difficulty with verbal paraphasia and right-hand limb-
kinetic apraxia at the age of 62 years of age, and was
diagnosed with CBS at 69 years of age. He had frontal
lobe signs such as forced grasping, total aphasia, and
right-limb kinetic apraxia; moreover, brain magnetic res-
onance imaging (MRI) demonstrated frontal and tem-
poral lobar atrophy dominantly affecting the left side
(Fig. 1a). The patient’s brother and parents had passed
away; therefore, we could not obtain their detailed
clinical information.
Neurological findings indicated that our patient was
lucid, but showed thought laziness. The cranial nerves,
including those related to eye movement, were normal.
The patient had normal muscle tonus and did not show
muscle weakness or involuntary movement, but all
extremity tendon reflexes were slightly increased. There
was no evidence of sensory impairment or cerebellar
ataxia. It was noted that speech required significant
effort, was slow and non-fluent, and showed anarthria
and aphasia. The patient’s Mini-Mental Scale Examin-
ation score was 4/30.
Language function was assessed using the Western
Aphasia Battery (WAB) Japanese edition once and SLTA
(standard language test of aphasia) two times within
2 months. The scores of WAB subtests were as follows:
spontaneous speech, 13 points; auditory verbal compre-
hension, 5.5 points; repetition, 0 points; naming, 0
points; reading, 4.3 points; writing, 2.2 points; praxis, 6.8
points; and construction, drawing, block design & calcu-
lation, 6.6 points. Raven’s score was 25/37 (aver-
age ± standard deviation: 26.9 ± 5.4). Aphasia quotient
was 36.8. The results of SLTA were similar to those of
Fig. 1 Brain MRI (axial T1-weighted images) of the patient’s brother (a) and the patient (b). a T1-weighted brain images of the patient’s brother
at 4 years after disease onset. Atrophy was predominantly observed in the left hemisphere affecting the frontotemporal lobes. b T1-weighted
brain images of the patient at 1 year after disease onset. Similar to her brother, atrophy was predominantly observed in the left hemisphere
affecting the frontal and temporal lobes
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WAB. Naming, writing, and repetition were impaired.
However, auditory verbal comprehension and reading
concerning words and short sentences were relatively
preserved. Spatial perception and visual perception were
also normal. Verbal comprehension via visual perception
was approximately normal. Therefore, it is likely that
auditory verbal comprehension was complemented by
visual perception. Constructional dysfunction, limb-
kinetic apraxia, ideational apraxia, and motor apraxia
were not observed. Laboratory blood examinations did
not reveal any particular abnormalities that could have
caused cognitive dysfunction. Cell counts and protein
concentrations in the patient’s cerebrospinal fluid were
within normal ranges, and concentrations of tau protein
(282 pg/mL) and phosphorylated tau protein (31.3 pg/
mL or lower) were also normal. Brain MRI demon-
strated cerebral atrophy dominantly affecting the left
frontotemporal lobes (Fig. 1b).
Clinically, the main patient symptoms were difficulty in
verbal expression and non-fluent aphasia in the absence of
visual memory impairment or behavioral abnormalities.
On this premise, the patient was diagnosed with PPA
according to Mesulam’s criteria [11]. Furthermore, the
aphasia was classified as non-fluent progressive aphasia
because, while speech itself required effort, the patient
retained knowledge about objects and the ability to under-
stand words. Brain MRI demonstrated cerebral cortical
atrophy dominantly affecting the left frontal and temporal
lobes, consistent with previous reports of non-fluent apha-
sia [4, 12]. Thus, FTLD was diagnosed according to the
patient’s clinical symptoms. Since the patient’s elder
brother had been diagnosed with CBS, and similar familial
cases of FTLD due to GRN and microtubule-associated
protein tau gene (MAPT) mutations had been reported
[13], we performed genetic analyses on the patient.
Genomic deoxyribonucleic acid (DNA) was extracted
from peripheral leukocytes isolated from the patient. The
exon/intron boundary of GRN was amplified by polymer-
ase chain reaction (PCR) according to a previously re-
ported method [2] and the PCR products were sequenced
in both directions. Briefly, blood was collected into a PAX-
gene® RNA tube, total ribonucleic acid (RNA) was ex-
tracted from the sample, and cDNA was prepared from
total RNA by a reverse transcriptase reaction. cDNA was
then amplified by reverse transcriptase–polymerase chain
reaction (RT-PCR) (forward primer: 5′-ACCCAGGCTGT
GTGCTG-3′; reverse primer: 5′-GACAGCCTCTGGG
ATTGGAC-3′) and the gene expression of GRN was
analyzed. Then, the amplified PCR product was extracted
and its sequence was analyzed.
The genetic examination identified a novel mutation
(c.1118_1119delCCinsG) in exon10 of GRN, which was
thought to cause a frameshift mutation (p.Pro373ArgX38).
No pathological mutations of MAPT were identified. The
GRN mRNA sequence was analyzed by RT-PCR; how-
ever, a mutant allele product was not detected,
suggesting degradation of the mutant allele by the
nonsense-mediated RNA decay system. Accordingly,
haploinsufficiency due to reduced expression of pro-
granulin was considered to be a possible pathogenic
mechanism of FTLD in these cases (Fig. 2).
Discussion and conclusions
Various types of mutations including aberrant splicing,
gene deletion, frameshift, and nonsense mutations of
GRN have been reported. These mutations are known to
cause familial FTLD via progranulin haploinsufficiency
[2, 3]. In the present case, our patient displayed PPA as
a main symptom of progranulin haploinsufficiency due
to a novel frameshift mutation of GRN. PPA, progressive
difficulties with word recall and usage, and language
comprehension impairments were apparent, whereas be-
havioral disinhibition, executive function, and memory
impairments were not impaired in the early stages of
disease (within 1 year after diagnosis). Other diseases
known to cause PPA include FTLD, Alzheimer’s disease
(AD), CBS, and Creutzfeldt–Jakob disease (CJD) [11];
however, a large number of studies reporting a link be-
tween GRN mutations and PPA suggest that GRN muta-
tions should always be considered in the differential
diagnosis of PPA. Similar symptoms, neuropsychological
profile, and neuroimaging findings have been reported
in a monozygotic twin pair with a GRN mutation [14].
In contrast, in our case, the patient’s brother presented
distinct phenotypic characteristics (i.e., FTLD with PPA
and CBS in the early stage). However, because the
patient’s brother had already passed away, we could not
obtain sufficient information to perform a genetic
Fig. 2 Genomic DNA and mRNA analyses. A sequential analysis of
genomic DNA obtained from the patient revealed a novel mutation
in GRN (c.1118_1119delCCinsG; p.Pro373ArgX38). RT-PCR analysis
using cDNA prepared from the patient’s peripheral lymphocytes revealed
no expression of the mutant allele, suggesting haploinsufficiency due to
nonsense-mediated mRNA decay
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analysis. Table 1 provides a summary of known cases of
GRN mutations that have been associated with familial
phenotypic heterogeneity. The presence of familial pheno-
typic heterogeneity with respect to symptoms such as cog-
nitive dysfunction and motor impairment has been
reported in 17 families with GRN mutations [4–10, 12–19].
These studies reported significant variations in age of onset
and mutation site, and motor neuron diseases were rela-
tively uncommon. Families have also been reported with
differing symptom laterality and different regions of brain
atrophy. In a genetic analysis of 48 Japanese families with
FTLD, PSP, or CBS [10], only one FTLD case with a GRN
Table 1 Familial cases presenting with distinct clinical phenotypes
Case Age onset; number of
patients
First symptom Phenotype Brain atrophy Ethnic origin GRN mutation
Rovelet-Lecrux
et al., 2008 [15]
67,77; 2 patients Language dysfunction PPA left > right French g.95_4390del
Resting tremor PD
Spina et al.,
2007 [13]
45,73; 2 patients Involuntary arm
movement
CBS right > left N/A g.26C >A
Cognitive decline AD
Beck et al.,
2008 [4]
54–67; 10 patients Language dysfunction PPA left > right
(n = 2)
United Kingdom g.90_91insCTGC
Limb apraxia CBS right > left
(n = 1)
Skoglund et al.,
2009 [12]
46–59; 10 patients Language dysfunction PPA N/A Swedish g.102delC
Limb apraxia CBS
Rademakers
et al., 2007 [16]
62,66; 2 patients N/A FTLD, CBS N/A American g.3240C > T
Masellis et al.,
2006 [17]
57,62; 2 patients Behavioral changes FTLD right > left Canadian family of
Chinese origin
g.1637G > A
Axial and extremity
rigidity
CBS
Leverenz et al.,
2007 [18]
35–69; 9 patients Language dysfunction FTLD left > right
(n = 3)
right > left
(n = 1)
American g.1871A > G
Anxiety, apathy PPA
Parkinsonism PD
López de Munain
et al., 2008 [19]
53,57; 2 patients N/A FTLD, CBS N/A Basque Country g.1872G > A
51,71; 2 patients N/A FTLD, CBS N/A Basque Country g.1873G > A
65; 2 patients N/A FTLD, CBS N/A Basque Country g.1874G > A
60; 2 patients N/A FTLD, CBS N/A Basque Country g.1875G > A
63–70; 4 patients N/A FTLD, CBS N/A Basque Country g.1876G > A
52; 2 patients N/A FTLD, ALS N/A Basque Country g.1877G > A
Benussi et al.,
2009 [5]
60–71; 5 patients Language dysfunction PPA right > left Italian g.1977_1980delCACT
Parkinsonism CBS
Kelley et al.,
2009 [6]
N/A; 6 patients N/A FTLD, PD symmetrical American g.2273_2274insTG
N/A; 6 patients N/A FTLD, PD right > left American g.2597delC
Pietroboni
et al., 2011 [7]
47–79; 5 patients Memory impairment,
Acalculia
FTLD, AD right > left
(n = 1)
symmetrical
(n = 1)
N/A (n = 3)
Italian g.63_64insC
Language impairment
Rossi et al.,
2011 [8]
47–80; 6 patients Behavioural
abnormality
FTLD
Dementia
Left > right Italian g.1761_1762delCA
Language dysfunction
Attention impairment
The present case 75,62; 2 patients Language dysfunction PPA left > right Japanese g.1118_1119delCCinsG
Limb apraxia CBS
AD Alzheimer’s disease, ALS amyotrophic lateral sclerosis, CBS corticobasal syndrome, FTLD frontotemporal lobar degeneration, GRN progranulin gene, N/A not
available, PD Parkinson’s disease, PPA primary progressive aphasia
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mutation was identified. Therefore, familial FTLD associ-
ated with GRN mutations is very rare. Furthermore, our re-
port is the first to describe in detail distinct phenotypes
within a family. Additional investigations of GRNmutations
mediating different clinical phenotypes of neurodegenera-
tion within a family are necessary.
As mentioned above, haploinsufficiency is thought to
underlie the mechanism of GRN mutation-associated
FTLD. Haploinsufficiency is a cause of autosomal gen-
etic conditions when the protein expressed by a single
allele is not sufficient to maintain its normal function
(loss of function) [20]. On the other hand, in many auto-
somal dominant conditions, toxic gain of function or
toxicity of excessive proteins are the cause of disease
[21, 22]. In fact, an approximate 50% decrease in mRNA
and 33% decrease in progranulin protein was reported in
one GRN mutation carrier [1, 2]. It has thus been sug-
gested that an effective therapeutic strategy would be to
increase progranulin levels in patients [1]. The relation-
ship between GRN genetic variability and the risk of de-
veloping a neurodegenerative disease such as AD or
MND has been reported [1]. Yet, the exact functions of
progranulin in the brain remain unclear, and its patho-
genic involvement in neurodegenerative disorders is not
known. Therefore, the accumulation of new cases of
GRN mutations that display distinct clinical phenotypes
within a family may be helpful not only for the elucida-
tion of progranulin function, but also for the develop-
ment of replacement therapies in FTLD and other
neurodegenerative diseases due to GRN mutations.
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